Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies (Nasdaq: DVAX) announced on May 4, 2021 that it granted nonstatutory stock options for 148,500 shares to seven newly-hired employees as an employment inducement. The options were awarded at an exercise price of $9.74 per share, equal to the stock's closing price on the grant date, May 3, 2021. These options have a 7-year term and vest over three years, with one-third vesting annually and remaining shares monthly. This initiative complies with Nasdaq Listing Rule 5635(c)(4) and is part of the 2021 Inducement Award Plan.
Dynavax Technologies announced findings from a post-marketing study presented at the 2021 Annual Conference on Vaccinology Research. The study, which included approximately 31,000 patients receiving HEPLISAV-B and 38,000 receiving Engerix-B, showed an acute myocardial infarction (AMI) rate of 1.67 for HEPLISAV-B versus 1.86 for Engerix-B. The hazard ratio of 0.92 indicates no increased AMI risk with HEPLISAV-B. These results confirm the safety profile of HEPLISAV-B, supporting its continued use in hepatitis B prevention.
Dynavax Technologies Corporation (Nasdaq: DVAX) will release its first quarter 2021 financial results on May 6, 2021, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company focuses on developing vaccines, with its first product, HEPLISAV-B®, already approved in the U.S. and EU for hepatitis B prevention in adults. Dynavax continues to advance its CpG 1018 adjuvant through collaborations for COVID-19, pertussis, and universal influenza vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) announces that Valneva SE has initiated a pivotal Phase 3 clinical trial for its COVID-19 vaccine candidate VLA2001, utilizing Dynavax's CpG 1018 adjuvant. The Cov-Compare trial aims to compare VLA2001 against AstraZeneca's Vaxzevria in a study involving 4,000 adults, focusing on the superior neutralizing antibody response. Following promising Phase 1/2 results, Valneva plans regulatory submission in autumn 2021 if Phase 3 results are favorable, marking a significant step in COVID-19 vaccine development.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that two abstracts related to its hepatitis B vaccine, HEPLISAV-B, will be presented at the 2021 Annual Conference on Vaccinology Research (ACVR) scheduled for April 26-27, 2021. The first abstract evaluates the safety and immunogenicity of HEPLISAV-B in adults undergoing hemodialysis, while the second presents findings on the occurrence of acute myocardial infarction in over 60,000 patients vaccinated with HEPLISAV-B compared to another vaccine. These presentations can be viewed on-demand until June 30, 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced positive results from Valneva's Phase 1/2 trial of its COVID-19 vaccine candidate, VLA2001, featuring Dynavax's CpG 1018 adjuvant. The trial involved 153 healthy adults aged 18 to 55, showing a 100% seroconversion rate for S-protein binding IgG in the high dose group. Valneva aims to start a pivotal Phase 3 trial by the end of April 2021, pending regulatory approval. VLA2001 is designed to prevent COVID-19 and may be modified for new variants.
Dynavax Technologies (Nasdaq: DVAX) announced the grant of nonstatutory stock options to purchase 142,000 shares to six new hires. The options, granted on April 1, 2021, have an exercise price of $9.73 per share, equaling the stock's closing price on that date. Each option has a 7-year term and vests over three years, tied to continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan, aimed at attracting talent in the biopharmaceutical sector.
Clover Biopharmaceuticals and Dynavax Technologies announced the dosing of the first participants in the global Phase 2/3 SPECTRA trial, evaluating Clover's S-Trimer COVID-19 vaccine candidate. This double-blind, randomized study aims to assess the vaccine's efficacy, safety, and immunogenicity in over 22,000 adults across multiple continents. An interim analysis is expected in mid-2021. The trial is fully funded by the Coalition for Epidemic Preparedness Innovations, with hopes of producing hundreds of millions of doses for global distribution, emphasizing the vaccine's stability and manufacturing potential.
Dynavax Technologies Corporation (Nasdaq: DVAX) will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference on March 9-10, 2021. CEO Ryan Spencer will lead the presentation, which will be available on demand starting at 7:00 a.m. E.T. on March 9, accessible via the Investors section of the company’s website. Dynavax specializes in developing vaccines, having commercialized HEPLISAV-B®, a hepatitis B vaccine, and is advancing CpG 1018 as a vaccine adjuvant for various collaborations.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of stock options totaling 350,000 shares to its newly appointed Senior Vice President and Chief Financial Officer, Ms. MacDonald, effective March 1, 2021. Additionally, the company issued 74,300 shares in stock options to four newly hired employees. These options have a 7-year term, vesting over three years, with an exercise price of $8.90, reflecting the closing price on the grant date. This move complies with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent amidst ongoing vaccine developments.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
